ClearPoint Neuro (NASDAQ:CLPT) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPS

ClearPoint Neuro (NASDAQ:CLPT) issued its quarterly earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.09), FiscalAI reports. The company had revenue of $10.88 million during the quarter, compared to the consensus estimate of $12.73 million. ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%.During the same quarter in the prior year, the business earned ($0.21) earnings per share.

Here are the key takeaways from ClearPoint Neuro’s conference call:

• Q2 revenue increased 18% year over year to $10.9 million, helped by IRRAflow, higher operating-room procedural volumes, and increased placement of ClearPoint, Prism, and IRRAflow equipment. Gross margin also improved to 62% from 60%.
• Management raised the priority of commercial readiness after partner regulatory updates suggested potentially faster paths to Phase III enrollment and approval. ClearPoint expects 10–15 partner trials to enroll patients over the next 18 months and is expanding clinical support internationally.
• The company took possession of its 30,000-square-foot CAL preclinical facility and signed its first multimillion-dollar GLP services statement of work, expected to be completed in the first half of 2027. Management believes the facility could eventually support more than $60 million in annual revenue versus roughly $8 million of prior capacity.
• ClearPoint reduced its 2026 revenue guidance to $48 million–$52 million as it shifts spending toward clinical support, regulatory expansion, CAL equipment, focused ultrasound, robotics, and Harmony software rather than traditional sales expansion. Cash declined to $29.4 million at June 30 after $15 million of operating cash burn through the first half, although management expects burn to decrease in the second half.
• Management estimates high-teens to approximately 20% revenue growth in 2027, with upside from CAL utilization, potential commercial approvals, and stocking orders from pharmaceutical partners. Commercial procedures could generate approximately $12,000–$15,000 per patient on average, with certain programs such as uniQure’s estimated at $15,000–$25,000.

ClearPoint Neuro Price Performance

Shares of CLPT stock opened at $15.38 on Tuesday. ClearPoint Neuro has a one year low of $8.27 and a one year high of $30.10. The company has a market capitalization of $461.25 million, a P/E ratio of -15.23 and a beta of 1.24. The company’s 50-day simple moving average is $15.46 and its two-hundred day simple moving average is $13.06. The company has a debt-to-equity ratio of 2.63, a current ratio of 5.79 and a quick ratio of 4.88.

Insider Buying and Selling at ClearPoint Neuro

In other news, Director Timothy T. Richards sold 5,415 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $12.17, for a total transaction of $65,900.55. Following the sale, the director directly owned 87,198 shares of the company’s stock, valued at $1,061,199.66. The trade was a 5.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lynnette C. Fallon sold 5,091 shares of ClearPoint Neuro stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $11.14, for a total value of $56,713.74. Following the sale, the director directly owned 48,227 shares of the company’s stock, valued at approximately $537,248.78. This represents a 9.55% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 108,349 shares of company stock valued at $1,796,118. 6.94% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Commonwealth Equity Services LLC boosted its stake in shares of ClearPoint Neuro by 1.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 65,557 shares of the company’s stock worth $897,000 after acquiring an additional 1,109 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in ClearPoint Neuro by 4.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,791 shares of the company’s stock worth $367,000 after acquiring an additional 1,204 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in ClearPoint Neuro during the fourth quarter worth $25,000. BNP Paribas Financial Markets lifted its holdings in ClearPoint Neuro by 2,435.2% during the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after purchasing an additional 2,143 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of ClearPoint Neuro by 1,079.0% in the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after purchasing an additional 2,158 shares during the period. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CLPT has been the topic of several recent analyst reports. B. Riley Financial increased their target price on shares of ClearPoint Neuro from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Stifel Nicolaus set a $16.00 price objective on shares of ClearPoint Neuro in a research report on Tuesday, June 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.